

OKLAHOMA BOARD OF NURSING
2915 North Classen Boulevard, Suite 524
Oklahoma City, OK 73106
(405) 962-1800

FORMULARY ADVISORY COUNCIL
Minutes – August 13, 2015

The Formulary Advisory Council to the Oklahoma Board of Nursing met on August 13, 2015. Written notice of the meeting was filed with the Secretary of State's Office on December 4, 2014. Notice was posted on the Oklahoma Board of Nursing web site. A notice agenda was also posted on the Cameron Building front entrance at 2915 North Classen Boulevard, Oklahoma City, Oklahoma, as well as the Board office, Suite 524, at 8:00 AM on August 10, 2015 and not less than 24 hours prior to the meeting.

Place of Meeting: Basement Conference Room, Cameron Building

Time of Meeting: 2:30 PM

Members Present:

Tim Anderson, DPh	Oklahoma Pharmacists Association
Mary Jane Fry, DPh	Oklahoma Pharmacists Association
Harold Ginzburg, MD, JD, MPH	Oklahoma State Medical Association
L. Harkess, APRN, CNM, CNP	Oklahoma Board of Nursing
Meri Hix, DPh, BCPS, CGP	Oklahoma Pharmacists Association
Deborah Booton-Hiser, APRN, CNP, PhD	Oklahoma Board of Nursing
Robert Holsey, DO, DPh	Oklahoma State Osteopathic Association
Susan Jones, Ph.D., APRN, CNS	Oklahoma Board of Nursing
Jay Kinnard, DPh	Oklahoma Pharmacists Association
Madhusudan Koduri, MD	Oklahoma State Medical Association
Robin Kimball-Potter, APRN, CNS	Oklahoma Board of Nursing

Members Absent:

Brent Bell, DO	Oklahoma State Medical Association
----------------	------------------------------------

Guests:

Kortney Duffy	SWOSU Pharmacy Student
A. Murray	SWOSU Pharmacy Student
Brantley Underwood	Walgreens Pharmacy Resident
Dr. Lucas Hennings	Saint Francis Hospital
Richard Steel	Saint Francis Hospital

Board Staff Representative:

Jackye Ward, MS, RN
Gina Stafford BSN, RN

1.0 Preliminary Activities

1.1 Call to Order: The meeting was called to order by Deborah Booton-Hiser, Chairperson, at 2:30 PM.

1.2 Declaration of quorum: A quorum was declared present.

2.0 Council decision regarding approval of council meeting minutes for August 14, 2014: It was moved (J. Kinnard) and seconded to approve the minutes of August 14, 2014.

Voting:

Yes: (9) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard,
T. Anderson, R. Holsey, S. Jones, R. Kimball-Potter

No: (0)

Absent: (3) B. Bell, L. Harkess, M. Koduri,

M. Koduri (2:55), and L. Harkess (2:40) arrived after vote

Motion carried.

3.0 Verbal reports requiring no action by committee:

3.1 Changes to the *Oklahoma Nursing Practice Act*: J. Ward summarized House Bill 1081 and proposed changes related to the *Oklahoma Nursing Practice Act*. The bill was signed by the Governor on April 21, 2014 and will become effective November 1, 2015.

3.2 Review of revisions of the *Rules of the Board*: J. Ward reported that the Governor had signed the declaration of approval/disapproval of this year's proposed permanent *Rules*. The Board of Nursing proposed permanent *Rules* which were adopted and submitted to the Governor and Legislature prior to April 1, 2015, were considered approved and finally adopted on June 8, 2015. Ms. Ward reviewed the changes that will become effective August 27, 2015.

3.3 Report on Medic Veteran to Licensed Practical Nurse Bridge Course Guideline: J. Ward reported Board approval of the Medic Veteran to Licensed Practical Nursing Bridge Course Guideline. Ms. Ward provided the history behind 59 O.S. § 567.20, and shared key elements of the

guideline. The guideline can be used by practical nursing education programs to transition medic veterans with prior military medical training and experience into practical nursing education programs.

- 3.4 Future of Nursing Education Regulation Task Force proposed changes to the *Rules*:** J. Ward gave a report regarding work of the task force and the recommended changes to the *Rules* presented to the Board.
- 3.5 Other:** G. Stafford reviewed the membership list and reported that currently two members have expired terms. The appointing association is aware of the term expiration dates. G. Stafford reviewed the Oklahoma Nursing Practice Act [59 O. S. § 567. 4a.9.c.]. Members with expired terms, may continue to serve beyond the term limit until a successor is appointed by the appointing authority.
- 4.0 Review the Request to Amend Exclusionary Formulary sent by Dr. Stevan Lahr:**

- **Discussion regarding removal of Clozapine from the Exclusionary Formulary:** Concerns were expressed regarding the need for additional data from the requesting party. Council members expressed curiosity as to where in the state problems are being experienced specific to APRNs not being able to prescribe Clozapine. The drug warnings and national registry requirements were reviewed and discussed. It was moved (H. Ginzburg) and seconded to deny Dr. Lahr's request to amend the Exclusionary Formulary by removal of Clozapine.

Voting:

Yes: (11) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard, T. Anderson, R. Holsey, S. Jones, R. Kimball-Potter, L. Harkess, M. Koduri

No: (0)

Absent: (1) B. Bell

Motion carried.

- 5.0 Review the Request to Amend Exclusionary Formulary sent by Dr. Jeffrey Cates:**

- **Discussion regarding removal of Clozapine from the Exclusionary Formulary:** It was noted that the request, address, and information provided by Dr. Jeffrey Cates was repetitive of the previously submitted request sent by Dr. Stevan Lahr. It was moved (J. Kinnard) and seconded to deny Dr. Cate's request at this time, and to request additional information from those submitting the requests to include numbers of

patients receiving the medication in Oklahoma per regions of the state, plus a rural needs analysis.

Voting:

Yes: (11) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard, T. Anderson, R. Holsey, S. Jones, R. Kimball-Potter, L. Harkess, M. Koduri
No: (0)
Absent: (1) B. Bell

Motion carried.

6.0 Review Clozaril (Clozapine) National Registry: Information regarding the National Registry was provided during the discussion of the request to amend the *Exclusionary Formulary* by removing Clozaril (Clozapine). It was noted that nationally Advanced Practice Nurse Practitioners could apply to the National Registry if they want order Clozaril (Clozapine). There was no motion or vote.

7.0 Review scope of practice regarding Clinical Nurse Specialist and Certified Nurse Practitioners: G. Stafford reviewed the *Oklahoma Nursing Practice Act* [59 O.S. § 567.3a.] and the *Oklahoma Board of Nursing Rules* [OAC 485: 10-15-6]. Also, a review of the *National Certifications Approved by the Oklahoma Board of Nursing* was provided by G. Stafford. It was noted that Advanced Practice Registered Nurses with prescriptive authority are allowed to prescribe within their scope of practice which would include a population and speciality. There was no motion or vote.

8.0 Review Request to Amend the Formulary sent by Richard E. Steele:

- Richard Steele, APRN-CNP and Dr. Lucas Henning, Saint Francis Hospital Emergency Department, presented the request to amend the Exclusionary Formulary by removal of Etomidate, Propofol, and Versed or to allow an exception for these medications to be ordered by an Acute Care Certified Nurse Practitioner during rapid sequence intubation. Richard Steele told the Council that he had queried other state nursing boards to ask if their state board had ever taken action on a Certified Nurse Practitioner for the order or administration of Etomidate or Ketamine. He stated that no Board could confirm action on a licensee. G. Stafford clarified that Ketamine was not part of Richard Steele's request. Dr. Hennings discussed the use of Etomidate in the emergency room setting. Dr. Hennings also discussed the use of Versed after the patient was intubated. Information for each drug had been provided to the council members prior to the meeting. After discussion, it was moved (J. Kinnard) and seconded that Etomidate, Propofol and Versed would remain

on the *Exclusionary Formulary* and an “exception” would be placed beside Etomidate and Versed. The exception would state, “may be ordered for rapid sequence intubation by an APRN who is appropriately certified, privileged and credentialed for rapid sequence intubation only.

Voting:

Yes: (11) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard, T. Anderson, R. Holsey, S. Jones, R. Kimball-Potter, L. Harkess, M. Koduri

No: (0)

Absent: (1) B. Bell

Motion carried.

It was moved (T. Anderson) and seconded to deny the removal or exception of Propofol from the Exclusionary Formulary, not allowing Advanced Practice Registered Nurses to order Propofol in any situation.

Voting:

Yes: (11) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard, T. Anderson, R. Holsey, S. Jones, R. Kimball-Potter, L. Harkess, M. Koduri

No: (0)

Absent: (1) B. Bell

Motion carried.

9.0 Review and recommendations to the Oklahoma Board of Nursing on the revisions to *Advanced Practice Nurses with Prescriptive Authority Exclusionary Formulary -#P-50B*:

- **Draft revisions proposed by staff:** G. Stafford reported the process for reviewing and revising the *Exclusionary Formulary*. Revisions included updating those drugs no longer included in the *2015 American Hospital Formulary Service Drug Information Book*.
- **Discussion regarding Etomidate and Versed:** G. Stafford clarified that the drugs would remain on the *Exclusionary Formulary* and an “exception” would be placed beside Etomidate and Versed. The exception would state, “may be ordered for rapid sequence intubation by an APRN who is appropriately certified, privileged and credentialed”.

- **Discussion regarding new drugs:** G. Stafford reviewed the list of new drugs. The council review drug information regarding Invega Trinza, a new drug with a boxed warning. The council determined the drug could be ordered by Advanced Practice Registered Nurses and did not need to be placed on the *Exclusionary Formulary*.
- **Other recommendations:** Dr. Koduri request that sublingual be removed for Buprenorphine. New language was added to clarify the exception for Buprenorphine.

It was moved (H. Ginzburg) and seconded to send the Exclusionary Formulary with discussed revisions to the Board for approval

Voting:

Yes: (11) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard, T. Anderson, R. Holsey, S. Jones, R. Kimball-Potter, L. Harkess, M. Koduri

No: (0)

Absent: (1) B. Bell

Motion carried.

- 10. Review and approval of the *Request to Amend the Formulary*:** A motion was made (Susan Jones) and seconded to send the *Request to Amend the Formulary* without changes to the Board for approval.

Voting:

Yes: (11) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard, T. Anderson, R. Holsey, S. Jones, R. Kimball-Potter, L. Harkess, M. Koduri

No: (0)

Absent: (1) B. Bell

Motion carried.

- 11. Council decision regarding election of chairperson and vice-chairperson:**

11.1 Motion made (T. Anderson) and seconded that D. Booton-Hiser serve as Chairperson.

Voting:

Yes: (11) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard, T. Anderson, R. Holsey, S. Jones, R. Kimball-

Potter, L. Harkess, M. Koduri

No: (0)
Absent: (1) B. Bell

Motion carried.

11.2 Motion made (T. Anderson) and seconded that H. Ginzburg serve as Vice Chairman

Voting:

Yes: (11) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard, T. Anderson, R. Holsey, S. Jones, R. Kimball-Potter, L. Harkess, M. Koduri
No: (0)
Absent: (1) B. Bell

Motion carried.

12.0 **Date for next meeting:** Motion made (Mary Jane Fry) and seconded for the next meeting date for the Formulary Advisory Council to be set for *Thursday, August 11, 2016, at 2:30 PM.*

Voting:

Yes: (11) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard, T. Anderson, R. Holsey, S. Jones, R. Kimball-Potter, L. Harkess, M. Koduri
No: (0)
Absent: (1) B. Bell

Motion carried.

13.0 **Adjournment:** There being no further business, motion made (J. Kinnard) and seconded for adjournment at 4:20 p.m.

Voting:

Yes: (11) M. Fry, D. Booton-Hiser, M. Hix, H. Ginzburg, J. Kinnard, T. Anderson, R. Holsey, S. Jones, R. Kimball-Potter, L. Harkess, M. Koduri
No: (0)
Absent: (1) B. Bell

Motion carried.